Determination of Oversulfated Chondroitin Sulfate and Dermatan Sulfate in Heparin Sodium Using Anion-Exchange Chromatography with UV Detection

Significance of the Topic

The safety and purity of pharmaceutical heparin is critical due to its widespread use as an anticoagulant in surgery and dialysis. Adulteration of heparin with oversulfated chondroitin sulfate (OSCS) has caused severe adverse reactions in patients. A reliable analytical method to detect OSCS and related impurities such as dermatan sulfate is essential to protect public health and ensure quality control in heparin manufacturing and distribution.

Objectives and Study Overview

This study describes the development and validation of an anion-exchange chromatography method with UV detection to separate and quantify dermatan sulfate and OSCS in heparin sodium. The work follows the revised United States Pharmacopeia (USP) Stage 2 monograph requirements. Key goals include achieving baseline resolution of target contaminants from heparin, meeting USP system suitability criteria, and ensuring robustness for routine quality testing.

Methodology

The procedure employs a gradient elution using sodium phosphate monobasic and sodium perchlorate mobile phases at pH 3.0. A small-bore anion-exchange column enables operation at low flow rate, minimizing solvent consumption. A 75-minute run separates heparin, dermatan sulfate, and OSCS within a single chromatogram, detected by UV absorbance at 202 nm. The method was evaluated for precision, reproducibility, retention stability, and ruggedness.

Used Instrumentation

• High-pressure gradient pump system with mixer and thermal compartment
• 2 mm IonPac AG11 guard column and AS11 analytical column
• Variable wavelength UV detector equipped with semi-micro PEEK flow cell
• Autosampler with temperature control and 100 µL sample syringe
• Chromatography data system for method setup, acquisition, and background subtraction

Main Results and Discussion

The optimized method resolved dermatan sulfate, heparin, and OSCS with USP resolution values of approximately 1.1 and 1.8 for the critical pairs. Dermatan sulfate and OSCS at 1% v/v in heparin were clearly separated from the main heparin peak. Intra-day and inter-day precision for heparin peak area was well below the 2% RSD USP limit. Column performance remained stable over 310 injections with minimal changes in retention times and resolution. Mobile phase pH variations from 2.9 to 3.1 had negligible impact on performance.

Benefits and Practical Applications

• Enables rapid screening of heparin for OSCS adulteration in quality control laboratories
• Low solvent and waste generation due to small column diameter and flow rate
• Complies with official pharmacopeial requirements for heparin identification
• Delivers robust performance suitable for routine batch release testing

Future Trends and Potential Applications

As demand for tighter heparin quality oversight grows, future work may focus on:

1. Integration with mass spectrometric detection for confirmatory analysis
2. Automation of sample preparation to increase throughput
3. Development of shorter columns and faster gradients to reduce run time
4. Extension of the method to other glycosaminoglycan impurities and new anticoagulant analogs

Conclusion

The described anion-exchange chromatography method provides a reliable, sensitive, and USP-compliant approach for detecting dermatan sulfate and OSCS in heparin sodium. Its robust performance and low resource requirements make it an effective tool for ensuring the safety and purity of heparin products.

References

1. United States Pharmacopeia Heparin Sodium Monograph, USP 32–NF 27, Stage 2 Revision
2. Guerrini M et al. Oversulfated Chondroitin Sulfate as a Heparin Contaminant, Nat. Biotechnol. 2008, 26, 669–675
3. Dionex Application Note on HPAE-PAD for Organic Impurities in Heparin (AN 233)